Balancing the tradeoffs in IVT: enzyme engineering, reaction optimization, and dsRNA control for safe, scalable RNA production
“The growing demand for RNA-based vaccines and therapeutics has exposed critical trade-offs in current in vitro transcription (IVT) workflows. To ensure safe and scalable RNA production, manufacturers must balance enzyme engineering, reaction optimization, and dsRNA control to improve efficiency without compromising quality.”
Institutions
- Merck Biopharma Co., Ltd. (Japan) (JP)
Publication Details
- Journal
- Vaccine Insights
- Published
- 2025-11-06
- DOI
- https://doi.org/10.18609/vac.2025.041
- Primary Topic
- RNA regulation and disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00